



Book nr	Presentation / publication	Title	Sessions / Topic	Presenter
<b>ORAL PRESENTATIONS</b>				
<b>Keynote lectures</b>				
1	Invited presentation	Lessons Learned from the Genetic Heterogeneity of Lymphoid Malignancies	H. Kaplan Lecture	M. Shipp
2	Invited presentation	Elucidating the enigmatic pathobiology of Hodgkin lymphoma	G. Bonadonna Lecture	R. Küppers
3	Invited presentation	25 years of antibody treatments for lymphoma	J. Ultmann Lecture	P. W. M. Johnson
<b>Plenary Session</b>				
4	Proffered presentation	Frontline intensified ABVD demonstrates superior efficacy than PET-adapted ABVD in advanced Hodgkin Lymphoma: the FIL-Rouge Phase 3 Trial by the Fondazione Italiana Linfomi	Plenary session	A. Pinto
5	Proffered presentation	Nivolumab(N)-AVD Improves Progression-Free Survival Compared to Brentuximab Vedotin(BV)-AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma (HL): Results of SWOG S1826	Plenary session	A. F. Herrera

6	Proffered presentation	Fourth generation huCART19-IL18 produces durable responses in lymphoma patients previously relapsed/refractory to anti-CD19 CAR T-cell therapy	Plenary session	J. Svoboda
<b>AACR - ICML Joint session</b>				
7	Invited presentation	Single cell omics in the study of B cell lymphoma	AACR-ICML Joint session	K. Basso
8	Invited presentation	Circulating tumor DNA (liquid biopsy)	AACR-ICML Joint session	D. Rossi
9	Invited presentation	AI-based trial design	AACR-ICML Joint session	O. Elemento
<b>Session 1 - Dissecting lymphomas at the single cell level</b>				
10	Invited presentation	The tumor microenvironment of Hodgkin lymphoma at single cell resolution	Session 1	C. Steidl
11	Invited presentation	Trajectories of lymphomagenesis	Session 1	B. Nadel
12	Invited presentation	Subclonal heterogeneity driving progression and transformation in chronic lymphocytic leukemia	Session 1	E. Campo
13	Proffered presentation	Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma	Session 1	I. Spasevska
<b>Session 2 - Lymphomas affecting the CNS</b>				
14	Proffered presentation	Identification of Genomic Biomarkers of Disease Progression and Survival in Newly-Diagnosed Primary CNS Lymphoma	Session 2	J. Rubenstein

15	Proffered presentation	Consolidative HCT-ASCT is superior to non-myeloablative chemo-immunotherapy in newly-diagnosed PCNSL - Updated results of the randomized phase III MATRix/IELSG43 trial	Session 2	G. Illerhaus
16	Proffered presentation	CAR-T cells radically modify the management of relapsed/refractory primary cerebral lymphomas. Real life results of the French LOC network	Session 2	S. Choquet
17	Proffered presentation	Phase 2 study of ibrutinib with temozolomide, etoposide, liposomal doxorubicin, dexamethasone, rituximab (TEDDi-R) for secondary CNS lymphoma	Session 2	M. Roschewski
18	Proffered presentation	Five-year results of a phase 2 study of CNS-oriented therapy with R-CHOP for untreated intravascular large B-cell lymphoma: Final analysis of the PRIMEUR-IVL study	Session 2	K. Shimada
<b>Session 3 - Treatment of aggressive lymphomas</b>				
19	Proffered presentation	A randomized trial of observation versus radiotherapy in primary mediastinal B-cell lymphoma patients with complete metabolic response after standard immunochemotherapy.	Session 3	A. J. Davies
20	Proffered presentation	R-CODOX-M/R-IVAC versus DA-EPOCH-R in Patients with newly diagnosed high-risk Burkitt lymphoma: Final results of a multi-center randomized HOVON/SAKK trial.	Session 3	M. Chamuleau
21	Proffered presentation	Biomarker-driven treatment strategy in high-risk large B-cell lymphoma (NLG-LBC-06 phase II trial): Impact of ctDNA and TP53 aberrations on clinical outcome	Session 3	S. Leppa
22	Proffered presentation	Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard of care in relapsed/refractory large B-cell lymphoma	Session 3	J. R. Westin
<b>Session 4 - CLL and Richter syndrome</b>				
23	Proffered presentation	FoxO1-Rictor axis induces Akt phosphorylation during CLL cell adaptation to BCR inhibitors: implications for combinatorial therapy	Session 4	L. Ondrisova

24	Proffered presentation	Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage chronic lymphocytic leukemia (CLL): Final results of the CLL12 trial	Session 4	P. Langerbeins
25	Proffered presentation	Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study	Session 4	O. Al-Sawaf
26	Proffered presentation	Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004	Session 4	T. Siddiqi
27	Proffered presentation	Efficacy and safety of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter Syndrome	Session 4	A. M. Frustaci
28	Proffered presentation	Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter's transformation	Session 4	C. Carlo-Stella
<b>Session 5 - Pediatric lymphomas</b>				
29	Invited presentation	Primary Mediastinal B-cell Lymphoma in Children, Adolescents, and Young Adults	Session 5	L. Giulino Roth
30	Invited presentation	Minimal disseminated and minimal residual disease in childhood and adolescent Non-Hodgkin Lymphoma	Session 5	W. Wössmann
31	Proffered presentation	Phase 2 KEYNOTE-667: Pembrolizumab in children and young adults with classical Hodgkin lymphoma (cHL) with slow early response to front-line chemotherapy	Session 5	L. Vinti
32	Proffered presentation	Analysis treatment outcome of 46 refractory/relapsed pediatric mature B cell lymphoma patients- multi- center experience from China	Session 5	Y. Zhang
33	Proffered presentation	Allogeneic hematopoietic stem cell transplantation with reduced-toxicity conditioning for pediatric relapsed or refractory ALK-positive anaplastic large cell lymphoma	Session 5	F. Knörr

34	Proffered presentation	Patterns of presentation and outcomes in Stage IV Hodgkin lymphoma: A report from the Children's Oncology Group (COG) AHOD1331 trial	Session 5	D. Casey
35	Proffered presentation	Landscape of driver mutations and their clinical impacts in Chinese pediatric patients with mature B-cell non-Hodgkin's lymphoma and T-cell lymphoblastic lymphoma	Session 5	Q. Zheng
36	Proffered presentation	ALK-positive anaplastic large cell lymphoma with variant ALK-fusion partner: a population-based analyses of the NHL-BFM study group	Session 5	C. Damm-Welk
37	Proffered presentation	Lung staging in pediatric Hodgkin Lymphoma: Staging Evaluation & Response Criteria Harmonization for Childhood, Adolescent & Young Adult HL (SEARCH for CAYAHL) consensus	Session 5	J. Seelisch
38	Proffered presentation	Quality of Life in Pediatric High-Risk Hodgkin Lymphoma Treated with Brentuximab-Based Intensive Chemotherapy—Comparison to Historical Treatment Cohort and Healthy Peers	Session 5	A.M. Feraco
39	Proffered presentation	Quantitative whole-body MRI for predicting treatment outcome in pediatric patients with aggressive non-Hodgkin lymphoma undergoing chimeric antigen receptor T cell therapy	Session 5	Y.X. Li
<b>Session 6 - Peripheral T-cell lymphomas</b>				
40	Proffered presentation	The genetic subtypes and the tumor microenvironment signatures are associated with distinct outcomes in peripheral T-cell lymphoma	Session 6	Y. Suehara
41	Proffered presentation	Romidepsin plus CHOP versus CHOP in Patients with Previously Untreated Peripheral T-Cell Lymphoma: final analysis of the Ro-CHOP trial	Session 6	V. Camus
42	Proffered presentation	Targeted agents combined with CHOP compared with CHOP as the first-line therapy for peripheral T-cell lymphoma: preliminary results from a phase 2 GUIDANCE-03 Trial	Session 6	W. Zhao
43	Proffered presentation	Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: Primary Analysis of the Multinational Pivotal Study Results (JACKPOT8)	Session 6	W. Kim

44	Proffered presentation	First in human study of AUTO4, a TRBC1-tragetting CART T cell therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-cell Lymphoma	Session 6	K. Cwynarski
<b>Session 7 - New CAR-T approaches</b>				
45	Proffered presentation	Phase 2 Study of Anbal-cel, Novel Anti-CD19 CAR-T therapy with Dual Silencing of PD-1 and TIGIT in Relapsed or Refractory Large B Cell Lymphoma - Interim Analysis Result	Session 7	W. Kim
46	Proffered presentation	Point-of-care anti-BCMA CAR T-cell therapy induces encouraging response rates in high-risk relapsed/refractory multiple myeloma	Session 7	H. Magen
47	Proffered presentation	Off-the-shelf CD30.CAR-modified Epstein-Barr Virus-specific T cells (CD30.CAR EBVSTs) provide a safe and effective therapy for patients with Hodgkin lymphoma (HL)	Session 7	C. A. Ramos
48	Proffered presentation	Durables responses with anti-CD19 allogeneic CAR T ALLO-501/501A in phase 1 trials of relapsed/refractory large B-cell lymphoma (r/r LBCL)	Session 7	F. L. Locke
49	Proffered presentation	High efficacy and favorable safety of 3rd generation CD20 CAR-T (MB-106) for outpatient treatment of follicular lymphoma (FL) – results of a single-institution trial	Session 7	M. Shadman
<b>Session 8 - Epigenetic mechanisms and targeted therapies in B- and T-cell lymphomas</b>				
50	Invited presentation	Epigenetic basis and Therapy of DLBCL	Session 8	A. Melnick
51	Invited presentation	Epigenetic regulation of immune microenvironment interactions in lymphoma.	Session 8	F. Lemmonier
52	Invited presentation	Epigenetic basis and therapy of follicular helper T-cell lymphomas	Session 8	M.R. Green

53	Proffered presentation	Super-enhancer hypermutation in DLBCL: role of alterations in the glucocorticoid receptor pathway	Session 8	E. Bal
<b>Session 9 - Lymphoma imaging</b>				
54	Proffered presentation	Baseline PET Radiomics Outperforms Clinical Risk Scores in Predicting Primary Mediastinal B-Cell Lymphoma Outcome: Insights from the IELSG37 Study	Session 9	L. Ceriani
55	Proffered presentation	Risk stratification of DLBCL with MVED2 score using integrative host adipose density and metabolic tumor characteristics compared to other indexes	Session 9	C. Thieblemont
56	Proffered presentation	Baseline SUV and early response, but not MTV, are associated with outcome in relapsed/refractory Hodgkin lymphoma patients treated with nivolumab in the CHECKMATE 205 trial	Session 9	S. F. Barrington
57	Proffered presentation	Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T-cell therapy outcome	Session 9	B. S. Imber
58	Proffered presentation	Radiomics reflecting both tumor and host features improves outcome prediction in follicular lymphoma	Session 9	L. Rebaud
<b>Session 10 - Hodgkin Lymphoma</b>				
59	Proffered presentation	Genetically Distinct Pathogenesis of Epstein-Barr Virus (EBV)-positive Versus EBV-negative Classical Hodgkin (cHL) Lymphoma	Session 10	E. Tiacci
60	Proffered presentation	Distinct Hodgkin lymphoma subtypes identified by noninvasive genomic profiling	Session 10	S. K. Aligi
61	Proffered presentation	Dual targeting of Hodgkin's Lymphoma by anti-CD30 CAR-T cells co-transduced with an anti-PDL1 costimulatory receptor to overcome the immunosuppressive microenvironment	Session 10	B. Falini

62	Proffered presentation	The prognostic impact of clinical factors and immunoarchitectural patterns for nodular lymphocyte-predominant Hodgkin lymphoma: an international study by GLOW	Session 10	M. S Binkley
<b>Session 11 - Marginal zone lymphoma</b>				
63	Proffered presentation	Marginal Zone Lymphoma International Prognostic Index (MZL-IPI): a prognostic score for the entire spectrum of marginal zone lymphomas. A FIL and SPORE-MER study	Session 11	S. Luminari
64	Proffered presentation	Staging FDG-avidity in extranodal marginal zone lymphoma (EMZL) by disease location	Session 11	J. P. Alderuccio
65	Proffered presentation	Rituximab and Ibrutinib Combination Is Safe and Effective in Untreated Splenic and Nodal Marginal Zone Lymphomas: Planned Subset Analysis of the IELSG47/MALIBU Phase II Study	Session 11	C. Thieblemont
66	Proffered presentation	The IELSG39 Trial: Efficacy of First-Line Chlamydia psittaci Eradication with a Six-Month Regimen of Doxycycline in Patients with Stage-I MALT Lymphoma of the Ocular Adnexae	Session 11	A. J. M. Ferreri
67	Proffered presentation	Immunotherapy alone versus chemoimmunotherapy as first-line treatment of marginal zone lymphoma (MZL): a real-world analysis	Session 11	A. J Olszewski
<b>Session 12 - Lymphoma biology</b>				
68	Proffered presentation	BTG2 super-enhancer mutations disrupt TFAP4 binding and dysregulate BTG2 expression in Diffuse Large B-cell Lymphoma	Session 12	E. Bal
69	Proffered presentation	Clonal architecture of relapsed or refractory follicular helper T-cell lymphoma: an ancillary study of the ORACLE trial, a LYSA study	Session 12	F. Lemonnier
70	Proffered presentation	Molecular characterization contributes to diagnosis and predicts outcome in primary mediastinal large B-cell lymphomas: a LYSA study	Session 12	V. Camus



71	Proffered presentation	Gene expression profiling of t(14;18)-negative CD23+ follicle center lymphoma demonstrates activation of the IL4/JAK/STAT6 pathway and a role in its pathogenesis	Session 12	T. Schade
72	Proffered presentation	Immunoglobulin class dictates transformation trajectory and BCR status of MYC/BCL2 double-hit lymphoma: biology and clinical implications	Session 12	S. Casola
<b>UCLI - ICML Joint Session</b>				
73	Invited presentation	Introduction of Lymphoma Database of National Health Commission of the People's Republic of China	UCLI-ICML Joint session	W. Liu
74	Invited presentation	1998-2023 Twenty-five years of commitment to improving our understanding of lymphoma	UCLI-ICML Joint session	E. Zucca
75	Invited presentation	Smart Start with Tislelizumab as the Front- line Treatment in Patients with High-risk Stage IIB and Advanced- stage Classical Hodgkin Lymphoma	UCLI-ICML Joint session	Z. Li
76	Invited presentation	Role of checkpoint inhibition in Germany	UCLI-ICML Joint session	P. Borchmann
77	Invited presentation	New Drug Development in Lymphoma of China Is Going Global	UCLI-ICML Joint session	K. Zhou
78	Invited presentation	New trends in lymphoma treatment in Western Countries	UCLI-ICML Joint session	P.L. Zinzani
<b>Session 13 - Follicular lymphoma</b>				
79	Proffered presentation	A "Functional Cure" May be Achievable in a Subset of Patients with Follicular Lymphoma treated with chemoimmunotherapy: 15-Year Follow-Up of Phase III SWOG-S0016	Session 13	M. Shadman

80	Proffered presentation	SAKK 35/14 randomized trial of rituximab with or without ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy	Session 13	E. Zucca
81	Proffered presentation	Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study	Session 13	P. L. Zinzani
82	Proffered presentation	Odronextamab in patients with relapsed/refractory follicular lymphoma (FL) grade 1–3a: Results from a prespecified analysis of the pivotal Phase II study ELM-2	Session 13	S. Novelli
83	Proffered presentation	Mosunetuzumab demonstrates durable responses in patients with relapsed/refractory follicular lymphoma and $\geq 2$ prior therapies: updated analysis of a pivotal Phase II study	Session 13	L. H. Sehn
84	Proffered presentation	Epcoritamab with rituximab + lenalidomide (R2) provides durable responses in high-risk follicular lymphoma, regardless of POD24 status	Session 13	D. Belada
<b>ESMO - ICML Special Lecture</b>				
85	Invited presentation	DOES IT MATTER HOW WE NAME LYMPHOMAS?	ESMO-ICML Special Lecture	J.O. Armitage
<b>Session 14 - Novel agents</b>				
86	Proffered presentation	High Complete Response Rate With TNB-486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Follicular Lymphoma: Interim Results From an Ongoing Phase 1 Study	Session 14	R. Nair
87	Proffered presentation	Phase 1b/2a study of AZD4573 (CDK9i) and acalabrutinib in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL)	Session 14	A. Danilov
88	Proffered presentation	Phase 1 Study Of JNJ-67856633, A First-In-Human MALT1 Inhibitor, In Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL) And Chronic Lymphocytic Leukemia (CLL)	Session 14	M. Hertzberg

89	Proffered presentation	Enhancer of zeste homolog 2 (EZH2) inhibitor SHR2554 in relapsed or refractory (r/r) peripheral T-cell lymphoma (PTCL): updated outcomes from the first-in-human phase 1 study	Session 14	Y. Song
90	Proffered presentation	Open-label phase 1/2 study of CC-99282, a cereblon E3 ligase modulator (CELMoD) agent ± rituximab, in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL)	Session 14	J. M. Michot
91	Proffered presentation	Combining CD19-4-1BBL (R07227166) with glofitamab is safe and shows early efficacy in patients suffering from relapsed or refractory B-cell Non-Hodgkin Lymphoma	Session 14	M. Dickinson
<b>Session 15 - Immunotherapy for aggressive lymphomas</b>				
92	Proffered presentation	Glofitamab plus polatuzumab vedotin demonstrates durable responses and a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma	Session 15	M. Hutchings
93	Proffered presentation	Odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL): Results from a prespecified analysis of the pivotal Phase II study ELM-2	Session 15	M. Poon
94	Proffered presentation	Subcutaneous epcoritamab induces deep, durable complete remissions in relapsed/refractory large B-cell lymphoma: longer follow-up from the pivotal EPCORE NHL-1 trial	Session 15	C. Thieblemont
95	Proffered presentation	Glofitamab monotherapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): extended follow-up and landmark analyses from a pivotal Phase II study	Session 15	M. Dickinson
96	Proffered presentation	Bispecific anti-CD20/19 CAR-T - Zamtocabatagene Autoleucel for relapsed/refractory DLBCL - Interim analysis results of DALY-II-USA Study	Session 15	M. Ulrickson
97	Proffered presentation	Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Final Analysis of ALYCANTE, a Phase 2 LYSA Study	Session 15	R. Houot
<b>Focus on... Mantle Cell Lymphoma</b>				

98	Proffered presentation	Five-year update of the first-line IMCL-2015 GELTAMO study. Prolonged molecular and clinical responses were observed after MRD-driven ibrutinib discontinuation	Focus on... session 1	E. Giné
99	Proffered presentation	Acalabrutinib with rituximab as first-line therapy for older patients with mantle cell lymphoma – a phase II clinical trial	Focus on... session 1	P. Jain
100	Proffered presentation	Very Long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study.	Focus on... session 1	C. Sarkozy
101	Proffered presentation	Ibrutinib-rituximab and venetoclax (IRV) followed by risk-stratified R-HyperCVAD/MTX in young patients with untreated mantle cell lymphoma – phase-II WINDOW-2 trial	Focus on... session 1	M. Wang
102	Proffered presentation	Pirtobrutinib in covalent BTK-inhibitor pre-treated mantle cell lymphoma: updated results, subgroup analysis from BRUIN with >3 years follow-up from start of enrollment	Focus on... session 1	C. Y. Cheah
103	Proffered presentation	Outcomes of autologous transplant, allogeneic transplant, and CAR T cell therapy in TP53 altered mantle cell lymphoma: a multi-institution retrospective analysis	Focus on... session 1	M. Messmer
<b>Focus on... Hodgkin Lymphoma</b>				
104	Proffered presentation	Correlation between progression-free and overall survival in patients with classical Hodgkin lymphoma: a comprehensive analysis of individual patient data from GHSG trials	Focus on... session 2	P. J. Bröckelmann
105	Proffered presentation	Early FDG-PET adapted treatment of limited stage Hodgkin lymphoma (HL): 10y long term follow-up analysis of the randomized Intergroup EORTC/LYSA/FIL H10 trial	Focus on... session 2	M. Federico
106	Proffered presentation	Pembrolizumab as first therapy for hodgkin lymphoma is deliverable in older or ABVD-ineligible patients, allows subsequent therapy, and gives adequate survival.	Focus on... session 2	M. J. Dickinson
107	Proffered presentation	Phase 2 trial of Nivolumab plus Adriamycin, Vinblastine, Dacarbazine (N-AVD) as Frontline Therapy in Older Adults with Hodgkin Lymphoma	Focus on... session 2	P. Torka

108	Proffered presentation	Avelumab monotherapy followed by a PET adapted chemotherapy approach in the first line treatment of classical Hodgkin Lymphoma: Initial results from the AVeNuE window study	Focus on... session 2	G. P. Collins
109	Proffered presentation	Favezelimab plus pembrolizumab in anti-PD-1-refractory classical Hodgkin lymphoma (cHL): Estimating the relative efficacy of favezelimab	Focus on... session 2	P. Armand
<b>Focus on... Ongoing Trials</b>				
OT01	Proffered presentation	SAKK 38/19: Assessing a ctDNA and PET-oriented therapy in patients with DLBCL. A multicenter, open-label, phase II trial.	Focus on... session 3	A. Stathis
OT02	Proffered presentation	REMoDL-A: A Randomised Phase II Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma (DLBCL) with Acalabrutinib – Ongoing trial	Focus on... session 3	V. S Radhakrishnan
OT03	Proffered presentation	Brentuximab Vedotin-Nivolumab alone and then with Rituximab-Cyclophosphamide-Doxorubicin-Prednisone as Frontline Therapy of Primary Mediastinal Large B-cell Lymphoma	Focus on... session 3	R. E. Steiner
OT04	Proffered presentation	MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 versus lenalidomide plus rituximab in patients with relapsed/refractory follicular or marginal zone lymphoma	Focus on... session 3	L. Sehn
OT05	Proffered presentation	SUNMO: Phase III trial of mosunetuzumab plus polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in relapsed/refractory aggressive non-Hodgkin lymphoma	Focus on... session 3	A. Pavlovsky
OT06	Proffered presentation	ZUMA-23: A Global, Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucef vs Standard of Care as First-Line Therapy in Patients With High-Risk Large B-Cell Lymphoma	Focus on... session 3	J. Westin
<b>Focus on... Liquid Biopsy and Minimal Residual Disease</b>				
110	Proffered presentation	Molecular clustering on ctDNA improves the prognostic stratification of DLBCL patients compared to ctDNA levels	Focus on... session 4	R. Moia

111	Proffered presentation	Circulating tumor DNA (ctDNA) status and clinical outcomes in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) in the POLARIX study	Focus on... session 4	A. F. Herrera
112	Proffered presentation	MRD-Negativity After Frontline DLBCL Therapy: Pooled Analysis of 6 Clinical Trials	Focus on... session 4	M. Roschewski
113	Proffered presentation	Early ctDNA clearance after CAR T-cell infusion predicts outcome in patients with Large B-cell lymphoma : results from ALYCANTE, a phase 2 LYSA study	Focus on... session 4	M. DELFAU-LARUE
114	Proffered presentation	Cell-free DNA kinetics decipher potential mechanisms of action of Ibrutinib combination therapy in mantle cell lymphoma (MCL)	Focus on... session 4	M. Khouja
115	Proffered presentation	Combined use of minimal residual disease monitoring and FDG-PET for outcome prediction in follicular lymphoma: results from the Fondazione Italiana Linfomi (FIL) FOLL12 trial	Focus on... session 4	S. Ferrero
<b>Focus on... Mechanisms of treatment resistance</b>				
116	Proffered presentation	Genomic evolution and resistance to pirtobrutinib in covalent BTK-inhibitor pre-treated chronic lymphocytic leukemia patients: results from the phase I/II BRUIN study	Focus on... session 5	K. Patel
117	Proffered presentation	Single-cell RNA-Seq of classic hairy cell leukemia reveals disease drivers linked to intrinsic treatment resistance and identifies DUSP1 as potential new therapeutic target	Focus on... session 5	J. Bohn
118	Proffered presentation	IL16 production is a mechanism of resistance to BTK inhibitors and to R-CHOP	Focus on... session 5	A. Arribas
119	Proffered presentation	Enhancer RNAs (eRNAs) play a role in the response to small molecules and in the development of acquired resistance in marginal zone lymphoma (MZL).	Focus on... session 5	S. Napoli
120	Proffered presentation	Harnessing BTKi therapy by CDK4/6i control of T cell surveillance	Focus on... session 5	S. Chen-Kiang

121	Proffered presentation	Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma	Focus on... session 5	P. Jain
<b>Focus on... T-Cell lymphomas</b>				
122	Proffered presentation	Lack of SMARCB1 expression characterizes a subset of peripheral T-cell lymphomas enriched in children and young adults	Focus on... session 6	A. Fischer
123	Proffered presentation	Chromatin Accessibility Profiling to Increase Diagnostic Accuracy and Refine Cell-of-Origin Classification of Mature T-Cell Lymphomas	Focus on... session 6	E. Julia
124	Proffered presentation	BRCA1/2 mutations impact on the development of breast implant-associated lymphoma (BIA-ALCL) in women with breast cancer reconstructed with textured breast implants.	Focus on... session 6	P. Ghione
125	Proffered presentation	A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for elderly patients with CCR4-positive adult T-cell leukemia/lymphoma.	Focus on... session 6	A. Utsunomiya
126	Proffered presentation	AFM13 in patients with CD30-positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL): Results from the Phase 2 REDIRECT study	Focus on... session 6	W. S. Kim
127	Proffered presentation	Lacutamab in patients with advanced mycosis fungoides (MF): efficacy results according to updated lymph node (LN) classification in the TELLOMAK study	Focus on... session 6	P. PORCU
<b>Focus on... CAR-T cell</b>				
128	Proffered presentation	Proteomic profiling identifies granzyme B inhibitor Serpin B9 as mediator of resistance to CAR T-cell and bispecific antibody treatment in nodal B-cell lymphoma	Focus on... session 7	B. J. Brinkmann
129	Proffered presentation	CART-SIE real life study: primary mediastinal B-cell lymphoma (PMBCL) have a superior outcome compared to large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel	Focus on... session 7	A. Chiappella

130	Proffered presentation	Impact of response to systemic bridging therapy on clinical outcomes and cytokine profile in patients receiving CAR T-cell therapy for aggressive B-cell lymphoma.	Focus on... session 7	B. Wills
131	Proffered presentation	Bendamustine lymphodepletion triggers reduced inflammatory cytokines and decreased toxicities after both 4-1BB- and CD28-costimulated CART19 for non-Hodgkin lymphoma	Focus on... session 7	G. Ghilardi
132	Proffered presentation	Prognostic scoring systems for severe CRS and ICANS after autologous anti-CD19 CAR T cells in large B-cell lymphoma: a DESCAR-T registry study from the LYSA	Focus on... session 7	P. Sesques
133	Proffered presentation	Severe hematological toxicity following CD19 CAR-T for relapsed/refractory LBCL is associated with suppressive immune dysregulation and limited CAR-T expansion	Focus on... session 7	K. Rejeski
<b>Focus on... Large B-cell and Double Hit lymphomas</b>				
134	Proffered presentation	MYC/BCL6 double hit lymphoma negative for t(3;8) BCL6::MYC fusion is associated with inferior survival, in contrast with t(3;8) positive pseudo-double hit lymphoma	Focus on... session 8	B. D. Maybury
135	Proffered presentation	High complete metabolic response rates with epcoritamab + R-CHOP in previously untreated (1L) high-risk DLBCL, including double-hit/triple-hit: EPCORE NHL-2 update	Focus on... session 8	L. Falchi
136	Proffered presentation	waveLINE-004: open-label, phase 2 study of zilovetamab vedotin (MK-2140) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)	Focus on... session 8	A. Fosså
137	Proffered presentation	Long-term responses with loncastuximab tesirine: updated results from LOTIS-2, the pivotal phase 2 study in patients with relapsed/refractory diffuse large b-cell lymphoma	Focus on... session 8	P. F. Caimi
138	Proffered presentation	Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line therapy in large B-cell lymphoma (TRANSFORM study): Subgroup analyses by prior therapy response	Focus on... session 8	L. J. Nastoupil
139	Proffered presentation	Comparative accuracy of alternative early measures of residual disease after CAR19 therapy of relapsed/refractory LBCL	Focus on... session 8	B. J. Sworder



<b>Focus on... Radiotherapy</b>				
140	Proffered presentation	Rituximab-Containing Combined Modality Therapy in Limited Stage Follicular Lymphoma: Mature follow up and derivation of a novel prognostic score from the TROG99.03 Trial	Focus on... session 9	M. MacManus
141	Proffered presentation	Radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR-T – The UK experience	Focus on... session 9	A. Kuhn
142	Proffered presentation	High rate of metabolic complete response after low dose radiotherapy and Obinutuzumab in early stage follicular lymphoma: Initial results of the GAZAL study (GLA 2018-3)	Focus on... session 9	K. Herfarth
143	Proffered presentation	Very low dose Radiation therapy for Indolent lymphoma: Comparing “Big Boom” (4Gy x 1) versus “Boom Boom” (2Gy x 2)	Focus on... session 9	C. Hajj
144	Proffered presentation	Salvage Radiotherapy in Relapsed/Refractory Large B-Cell Lymphoma After CAR T-Cell Therapy Failure	Focus on... session 9	C. Patel
145	Proffered presentation	Bone marrow volume irradiated and risk of cytopenias in aggressive B-cell lymphoma patients bridged with radiation therapy for CART cell therapy	Focus on... session 9	B. S. Dabaja
<b>Focus on... Lymphoma microenvironment</b>				
146	Proffered presentation	Immune contexture analysis in POLARIX suggests response to Pola-R-CHP treatment reduces tumor microenvironment dependency	Focus on... session 10	F. Morschhauser
147	Proffered presentation	Spatially-resolved transcriptomics define clinically relevant subsets of macrophages in diffuse large B-cell lymphoma	Focus on... session 10	A. D Jeyasekharan
148	Proffered presentation	Coordinated changes in the tumor microenvironment (TME) are associated with increased risk of therapeutic failure in newly diagnosed diffuse large B-cell lymphoma (DLBCL)	Focus on... session 10	J. C. Villasboas

149	Proffered presentation	EZH2 inhibition enhances CAR T antitumor effect by inducing lymphoma immunogenicity and enhancing T cell function	Focus on... session 10	W. Béguelin
150	Proffered presentation	Single cell analysis reveals immune dysfunction in large B cell Lymphoma (LBCL) pts with hypomagnesemia receiving Axi-cel: results from ZUMA-1 trial and Mayo Clinic cohort	Focus on... session 10	P. Mondello
151	Proffered presentation	Follicular lymphoma patient-derived organoids for bispecific T-cell engager immunotherapy	Focus on... session 10	J. G. Schroers-Martin
<b>Focus on... Long term results of CLL trials</b>				
152	Proffered presentation	5-Year (Y) Follow-up of a Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) as Initial Therapy for Younger CLL Patients (Pts)	Focus on... session 11	I. E Ahn
153	Proffered presentation	Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL	Focus on... session 11	J. D Soumerai
154	Proffered presentation	Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) CLL/SLL: Extended follow-up of the SEQUOIA study	Focus on... session 11	M. Shadman
155	Proffered presentation	Fixed-duration ibrutinib + venetoclax in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study	Focus on... session 11	P. Ghia
156	Proffered presentation	MURANO: Final 7 year follow up and retreatment analysis in venetoclax-rituximab (VenR)-treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)	Focus on... session 11	J. Seymour